Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Slides:

Advertisements

Similar presentations

Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy Erik Wambre, PhD, Jonathan.

Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: A randomized, double-blind, placebo-controlled trial Kaarina.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Allergen immunotherapy: A practice parameter third update

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis Alain Didier, MD,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.

Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy Harold Nelson, MD, Shannon Cartier, MSc,

Is 9 more than 2 also in allergic airway inflammation?

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber Friedrich Horak, MD, Petra.

Treatment with grass allergen peptides improves symptoms of grass pollen–induced allergic rhinoconjunctivitis Anne K. Ellis, MD, MSc, FRCPC, Charles.

Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract Sheila M. Amar, MD, Ronald.

Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial Laila Hellkvist, MD,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season Alexander Kettner, PhD, Gilles DellaCorte, MD,

Antibiotic use in infancy and symptoms of asthma, rhinoconjunctivitis, and eczema in children 6 and 7 years old: International Study of Asthma and Allergies.

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind,

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Phillip Lieberman, MD, Michael Tankersley, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo- controlled clinical trial Peter Bager, PhD, John Arnved, MD, Steen.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma Oliver.

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis Stephen R. Durham,

Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: A randomized, double-blind clinical trial Michael Weschta, MD, Dagmar Rimek,

Cockroach allergens: Coping with challenging complexity

Autophagy: Nobel Prize 2016 and allergy and asthma research

Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber Thomas Werfel, MD, Annice Heratizadeh, MD, Margarete.

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study Giovanni B. Pajno,

Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen Carmen Rondón, MD, PhD, Natalia.

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years Ronald Dahl, MD,

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD

Seasonal rhinitis and azelastine: Long- or short-term treatment

Association between climate factors, pollen counts, and childhood hay fever prevalence in the United States Jonathan I. Silverberg, MD, PhD, MPH, Marc.

Reply Journal of Allergy and Clinical Immunology

Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis

Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis Philippe-Jean Bousquet, MD, Christophe Combescure, PhD,

Thunderstorm-related asthma attacks

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization.

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen Piyush Patel, MD, Tom Holdich, MBBS,

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: A systematic review and indirect comparison Janine Dretzke, MSc, Angela Meadows,

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial Jonathan M. Spergel,

Presentation transcript:

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study Gabriela Senti, MD, Seraina von Moos, MD, Fabian Tay, MD, Nicole Graf, PhD, Theodor Sonderegger, MSc, Pål Johansen, PhD, Thomas M. Kündig, MD Journal of Allergy and Clinical Immunology Volume 129, Issue 1, Pages 128-135 (January 2012) DOI: 10.1016/j.jaci.2011.08.036 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Participant flow. Flow diagram characterizing the study progress and participant flow through the different trial phases. Syst, Systemic. Journal of Allergy and Clinical Immunology 2012 129, 128-135DOI: (10.1016/j.jaci.2011.08.036) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Patient-reported treatment outcome. Patients rated the general improvement/deterioration of hay fever symptoms on a scale from −100 (worst possible deterioration) to +100 (best possible improvement) during the seasons 2008 (treatment) and 2009 (follow-up). Box plots show the median, the 10th, 25th, 75th, and 90th percentiles, and outliers. Intergroup comparison by Mann-Whitney multiple testing with Hochberg procedure adjustment. ∗P < .05. Journal of Allergy and Clinical Immunology 2012 129, 128-135DOI: (10.1016/j.jaci.2011.08.036) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Mean VAS symptom score for pollen season 2008 (upper panel) and 2009 (lower panel). Mean weekly VAS symptom scores (except lung symptoms) of the 100HEP group compared with those of the placebo group (left axis). For each patient, the sum of all symptom scores was calculated and divided by the number of symptoms. The continuous line shows the weekly pollen counts in Zurich (right axis). Journal of Allergy and Clinical Immunology 2012 129, 128-135DOI: (10.1016/j.jaci.2011.08.036) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Local drug-related AEs. A, Numbers of the most frequent local drug-related AEs as reported in the different treatment groups. B, Frequency of local side effects per patch sequence. Distribution of the frequency of local AEs was tested by using the χ2 test. Journal of Allergy and Clinical Immunology 2012 129, 128-135DOI: (10.1016/j.jaci.2011.08.036) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions